Country: Canada
Language: English
Source: Health Canada
RALTEGRAVIR (RALTEGRAVIR POTASSIUM)
MERCK CANADA INC
J05AJ01
RALTEGRAVIR
600MG
TABLET
RALTEGRAVIR (RALTEGRAVIR POTASSIUM) 600MG
ORAL
60
Prescription
HIV INTEGRASE INHIBITORS
Active ingredient group (AIG) number: 0152351004; AHFS:
APPROVED
2017-06-21
ISENTRESS® AND ISENTRESS HD®_ (raltegravir potassium)_ _ _ _Page 1 of 69_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION ISENTRESS® (*as raltegravir potassium) *Raltegravir tablets, 400 mg *Raltegravir chewable tablets, 25 mg, 100 mg ISENTRESS HD® (as raltegravir potassium) Raltegravir tablets, 600 mg Human immunodeficiency virus integrase strand transfer inhibitor Merck Canada Inc. 16750 route Transcanadienne Kirkland QC Canada H9H 4M7 www.merck.ca Date of Initial Authorization: November 9, 2007 Date of Revision: OCT 30, 2023 Submission Control Number: 276444 _ _ ISENTRESS® AND ISENTRESS HD®_ (raltegravir potassium)_ _ _ _Page 2 of 69_ RECENT MAJOR LABEL CHANGES 7 WARNINGS AND PRECAUTIONS 7.1 SPECIAL POPULATIONS 06/2022 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED . RECENT MAJOR LABEL CHANGES ............................................................................................ 2 TABLE OF CONTENTS .............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ...................................................................... 4 1 INDICATIONS ............................................................................................................... 4 1.1 Pediatrics ................................................................................................................... 4 1.2 Geriatrics ................................................................................................................... 4 2 CONTRAINDICATIONS ................................................................................................. 4 4 DOSAGE AND ADMINISTRATION ................................................................................. 4 4.1 Dosing Considerations ............................................................................................... 4 4.2 Recommended Dose and Dosage Adjustment ............................ Read the complete document